Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DMT210

Small molecule · developed by Dermata Therapeutics

Phase 2 Most advanced trial (none active)

DRMA Developer

2 Registered trials

What is DMT210?

DMT210 is a topical aqueous gel formulation applied twice daily, studied in atopic dermatitis and acne rosacea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Dermatology
Developer: Dermata Therapeutics (DRMA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03003104	Phase 2	Acne Rosacea	Completed	DRMA
NCT02949960	Phase 2	Atopic Dermatitis	Completed	DRMA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acne RosaceaAtopic Dermatitis

More from Dermata Therapeutics

DMT310 Phase 3

Sources

ClinicalTrials.gov NCT02949960

Updated Oct 3, 2026. Something wrong or missing? Report it on the DRMA page.

Follow DRMA, the company behind DMT210

See DRMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DRMA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z